The Studies onAdjuvant Chemotherapy for Dukes B Colorectal Carcinoma

Ye Yingjiang,Wang Sha,Zhou Jing
DOI: https://doi.org/10.3969/j.issn.1000-8179.2007.03.007
2007-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To evaluated the efficacy and safety of the postoperative adjuvant FCF chemotherapy for patients with colorectal carcinoma(Dukes B). Methods: A total of 102 patients with Dukes B stage bowel carcinoma, who had undergone curative resection alone(CRA group) or received FCF-based postoperative adjuvant chemotherapy(FCF group), were reviewed. The end-point was 5-year survival rate and 3-year disease-free survival rate. The side effects were recorded. Results: After a median follow-up of 41 months, The rate of 3-year disease-free survival was 80.0%and 62.5%(P=0.019) respectively for the FCF group and CRA group. The 5-year survival rate for patients with Dukes B stage colorectal carcinoma in each group was 89.97% and 66.73%(P<0.05) respectively for the FCF group and CRA group. The main side effects include anorexia, nausea/vomiting, alopecia and pigmentation. Most of the side effects were tolerable and mild. Conclusion: Postoperative adjuvant FCF chemotherapy improves 3-year disease- free survival rate and the 5-year survival rate of the patients with Dukes B stage colorectal carcinoma. The regimens of FCF are tolerant and safe.
What problem does this paper attempt to address?